ArticleNeurology2021
Progression of Clinical Features in Lewy Body Dementia Can Be Detected Over 6 Months.
Article in Neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 36 citations in OpenAlex.
- Efficacy of Adjunctive Therapy with Zonisamide Versus Increased Dose of Levodopa for Motor Symptoms in Patients with Dementia with Lewy Bodies: The Randomized, Controlled, Non-Inferiority DUEL Study.Journal of Alzheimer's disease : JAD · 2023Trial
- A Phase 2b randomized clinical trial of the oral p38α inhibitor neflamapimod in dementia with Lewy bodies (DLB).Research square · 2026Article
- Thresholds for meaningful change in Mini-Mental State Examination scores in rare dementias.Alzheimer's research & therapy · 2026Article
- NADAlzheimer's & dementia : the journal of the Alzheimer's Association · 2026Review
- Comparing phenotypic features between Parkinson's disease dementia and dementia with Lewy bodies.Journal of neurology · 2026Article
- Implications and opportunities regarding biological frameworks in overt and prodromal dementia with Lewy bodies.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- Case Study 8: A 70-Year-Old Man With Memory Loss, Wandering, and Inappropriate Behaviors.The Journal of neuropsychiatry and clinical neurosciences · 2025Article
- What is the future for dementia with Lewy bodies?Journal of neurology · 2024Review
- Differences in the treatment needs of patients with dementia with Lewy bodies and their caregivers and differences in their physicians' awareness of those treatment needs according to the clinical department visited by the patients: a subanalysis of an observational survey study.Alzheimer's research & therapy · 2024Article
- Factors Associated with Quality of Life in Patients with Dementia with Lewy Bodies: Additional Analysis of a Cross-Sectional Study.Journal of Alzheimer's disease : JAD · 2024Article
- Developing a person-centered stated preference survey for dementia with Lewy bodies: value of a personal and public involvement process.Frontiers in dementia · 2024Article
- Longitudinal motor decline in dementia with Lewy bodies, Parkinson disease dementia, and Alzheimer's dementia in a community autopsy cohort.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023Article
- Cognitive and Motor Decline in Dementia with Lewy Bodies and Parkinson's Disease Dementia.Movement disorders clinical practice · 2023Article
- Race and Ethnicity in Lewy Body Dementia: A Narrative Review.Journal of Alzheimer's disease : JAD · 2023Review
- Specific neuropsychiatric symptoms are associated with functional decline trajectories in Alzheimer's disease and Lewy body dementia: a five-year follow-up study.Frontiers in medicine · 2023Article
- Clinical outcome measures in dementia with Lewy bodies trials: critique and recommendations.Translational neurodegeneration · 2022Review
- Lewy Body Dementias: Controversies and Drug Development.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022Review
- A common outcome set for trials in dementia with Lewy bodies (DLB COS).Alzheimer's & dementia (New York, N. Y.)Article
- The utility of a composite endpoint for tracking disease progression in Lewy body dementia.Alzheimer's & dementia (New York, N. Y.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to quantify the trajectory and magnitude of change of the key clinical features and corresponding symptom domains of dementia with Lewy bodies (DLB) and Parkinson disease dementia (PDD), including global cognition, parkinsonism, recurrent visual hallucinations, cognitive fluctuations, and sleep disturbance.
methodsOne hundred sixteen patients with Lewy body dementia (DLB = 72, PDD = 44) underwent assessment at baseline and 3 and 6 months as part of a prospective multicenter randomized controlled trial. Linear mixed models were constructed for core outcome measures using the Mini-Mental State Examination (MMSE), motor section of the Unified Parkinson's Disease Rating Scale (UPDRS-III), Dementia Cognitive Fluctuations Scale (DCFS), and Neuropsychiatric Inventory (NPI).
resultsWithin the time frame of our study (6 months), we were able to identify a significant cognitive decline of 1.3 points on the MMSE ( DISCUSSION: Clinically significant rates of change in core clinical features can be detected and quantified in Lewy body dementia over a relatively short period (6 months) using common clinical instruments and thus may be useful as clinical endpoints for therapeutic trials of disease-modifying and symptomatic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.